Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215910 · ClinicalTrials.gov registry record · Phase 3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT07215910 is a Phase 3 study that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 408 participants.
The verdict
NCT07215910, a Phase 3 study, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.
Interventions
- DRUG Temozolomide
- RADIATION Intensity-Modulated Radiation Therapy
- PROCEDURE Intensity-Modulated Proton Therapy
- RADIATION Volume Modulated Arc Therapy
- RADIATION Pencil Beam Scanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2040-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215910
The ClinicalTrials.gov registry entry for NCT07215910 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT07215910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07215910 about?
NCT07215910 is a clinical study titled "Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer". This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deo...
What is the current status of trial NCT07215910?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2026-07-20. Estimated completion is 2040-01.
What interventions are being tested in trial NCT07215910?
The interventions under investigation include: Temozolomide (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Intensity-Modulated Proton Therapy (PROCEDURE), Volume Modulated Arc Therapy (RADIATION), Pencil Beam Scanning (RADIATION).
Who is sponsoring clinical trial NCT07215910?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.